



Financial Statements
for the 3rd quarter of fiscal year ending March 31, 2019
(From Apr. 1, 2018 to Dec. 31, 2018)

Summary of consolidated results

JMS Co., Ltd.

Company Code No. 7702

February 7, 2019

Highlights in Business Results



(unit: JPY million)

	Apr. - Dec. 2017 Results	Apr. - Dec. 2018 Results	Diff.	Year-over- Year
Net sales	41,983	44,251	2,267	5.4%
Operating profit	548	1,374	826	150.6%
Ordinary profit	713	1,419	706	99.0%
Profit attributable to owners of parent	497	980	482	96.9%
Basic earnings per share※	JPY 20.43	JPY 40.22	---	---

Exchange Rate (average during period)	US Dollar	111.70	111.14
	Euro	124.55	130.97
	(unit: JPY) Singapore Dollar	81.60	81.80

**Increased in sales (2nd straight year)
and increased in profit.**


Sales	Japan	-Increased sales of New Hemodialysis Machine “GC-X01” and Dysphagia related products	Profit	-The influence of increased sales and the decrease of selling cost, resulted in profit increase
	Overseas	-Increased sales of Apheresis kit		

※We have conducted a share consolidation of common stock of JMS Co., Ltd. pursuant to which two (2) shares were consolidated into one (1) share effective as of October 1, 2017. Accordingly, the “Net income per share” has been calculated assuming that such share consolidation has been conducted at the beginning of the previous fiscal year.

Summary by segment (geographical area)

(unit: JPY million)

Japan




[Sales]

Increased sales of New Hemodialysis Machine "GC-X01" and Dysphagia related products raised net sales.

[Ordinary profit]

The decrease of selling cost resulted in profit increase.

Singapore*



[Sales]


Increased sales of Apheresis kit for North America market raised net sales.

[Ordinary profit]

The influence of increase sales resulted in profit increase.

*This segment includes Indonesia local subsidiary.

China



[Sales]

Decreased sales of Infusion Sets for Japan market due to production transfer to Philippines reduced net sales.


[Ordinary profit]

The influence of decreased labor cost and expense resulted in profit increase.

Summary by segment (geographical area)

(unit: JPY million)

Philippines




[Sales]

Increased sales of Infusion Sets for Japan market raised net sales.

[Ordinary profit]

The influence of increased sales reduced loss.

Others *



*This segment includes business activity of domestic subsidiaries, Germany, United States and South Korea.

~Product introduction~




Hemodialysis Machines


Hemodialysis machine is a device for pulling blood from a patient into an extracorporeal circuit. The blood is purified by a dialyzer and returned to the patient by the hemodialysis machine.

Sales by Business Segment


Apr. – Dec. 2017
 Apr. – Dec. 2018
 (unit: JPY million)



Sales change by Region (Customer's Location)




(unit: JPY million)



Selling, General and Admin. Expenses



(unit: JPY million)



(unit: JPY million)

	Apr. - Dec. 2017	Apr. - Dec. 2018	Diff.	Year-over-Year
Labor Cost	4,345	4,372	27	0.6%
Transport	1,210	1,244	33	2.8%
R & D	1,072	1,147	74	7.0%
Depreciation	258	248	(9)	(3.8%)
Others	3,334	3,148	(185)	(5.6%)
Total	10,221	10,161	(59)	(0.6%)

[R & D]

Clinical trial expense for the development of a new product continued.


[Others]

Sales commission decreased.

Ordinary profit : Compared with the previous year



(unit: JPY million)



The underlined figures exclude impact of exchange rate.

Forecast for FYE Mar. 2019



(unit: JPY million)

	FYE Mar. 2018 Result	FYE Mar. 2019 Forecast		
		Previous Forecast	New Forecast	Year -over- Year
Net sales	56,520	58,000	58,000	2.6%
Operating profit	573	1,000	1,500	161.4%
Ordinary profit	820	1,200	1,500	82.8%
Profit attributable to owners of parent	631	800	1,100	74.3%
Basic earnings per share	JPY 25.91	JPY 32.83	JPY 45.13	---

Exchange Rate (average during period)	US Dollar	110.85	105	111
	Euro	126.67	130	130
	(unit: JPY) Singapore Dollar	81.74	82	82

Consolidated business forecast for the fiscal year ending March 31, 2019 has been revised, due to the before-mentioned business results.

Topics



※Announcement date

-Announcement of finished the production of Ono Plant

Sep. 26, 2018

-Announcement of disposition of treasury shares as the stock compensation plan with transfer restrictions

Jul. 18, 2018

-Announcement of introduction of the stock compensation plan with transfer restrictions

May. 18, 2018

-Launching new product “TWIN SHIELD” , Catheter connection system

Apr. 18, 2018



「TWIN SHIELD」



The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.